Viewing nowSamsung Pregabalin Capsule 75mg
Pregabalin 75mg
Hard capsule · Prescription medication
Samsung Pharmaceutical Co., Ltd.

MFDS item code 201603279 · Approved 2016.06.08 · Insurance code 642306780
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment for partial-onset seizures
This medication is used to alleviate peripheral and central neuropathic pain in adults. It is also prescribed as an adjunct for patients with epilepsy who experience partial seizures. It can help reduce pain and discomfort caused by fibromyalgia. Thus, it is effective in managing various neurological disorders and pain.
This medicine is administered orally as pregabalin, with the total daily dose divided into 2 doses, regardless of food. 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: The starting dose of this medicine may be 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may thereafter be increased at 7-day intervals up to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The starting dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased to 150 mg twice daily (300 mg/day) within 1 week. For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased to 225 mg twice daily (450 mg/day) within 1 week. Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with renal impairment The dose should be adjusted in patients with impaired renal function. Creatinine clearance ≥60 (mL/min): starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance ≥30 -<60 (mL/min): starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance ≥15 -<30 (mL/min): starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance <15 (mL/min): starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as indicated in the dosing regimen. b: Supplemental dose refers to an additional dose administered once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age and adolescent patients aged 12 to 17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This medication may increase the risk of suicidal thoughts or behaviors, so mood changes or behavioral changes should be closely monitored while taking it. Patients with hypersensitivity to this medication or certain hereditary diseases like lactose intolerance should not take it. Diabetic patients should be cautious as weight gain may require adjustments in diabetes control medications. If symptoms of angioedema occur, the medication should be discontinued immediately and medical advice should be sought. Elderly patients should be particularly careful at the beginning of treatment due to risks of dizziness and drowsiness. Visual disturbances or other changes in vision may occur, and these symptoms may improve upon discontinuation of the medication. If this medication is suddenly stopped, withdrawal symptoms such as insomnia, headache, nausea, and anxiety may appear, so it should be gradually discontinued according to medical guidance. Patients with a history of drug abuse may have a higher risk of misuse of this medication, so caution is needed during use. Patients with impaired renal function may require dosage adjustments. Patients with heart disease should be cautious when taking this medication, especially those with congestive heart failure, and should use it judiciously. Taking this medication with other central nervous system depressants may increase the risk of respiratory depression, so caution is advised. During early pregnancy, there is a risk of fetal malformations, so pregnant women should avoid taking it, and women of childbearing age should use effective contraception. Breastfeeding women are advised to either discontinue breastfeeding or stop taking this medication, as it may pass into breast milk. Activities that require driving or operating machinery should be avoided until dizziness or drowsiness resolves. Overdose may cause confusion, drowsiness, depression, etc., so immediate medical attention is necessary, and blood dialysis may be required if indicated. Keep out of reach of children, and take care not to transfer to other containers.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture. It is also advisable to store it at a proper temperature between 15 to 30 degrees Celsius, avoiding excessively hot or cold environments.
A hard capsule with a reddish-brown upper part and a white lower part containing a white to light yellow powder.
30 capsules per bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Samsung Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.